Eyegate Pharmaceuticals (NASDAQ: EYEG) and Galena Biopharma (NASDAQ:GALE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Risk & Volatility

Eyegate Pharmaceuticals has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500. Comparatively, Galena Biopharma has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.


This table compares Eyegate Pharmaceuticals and Galena Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%
Galena Biopharma N/A -76.75% -28.16%

Insider and Institutional Ownership

13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.5% of Galena Biopharma shares are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Galena Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Eyegate Pharmaceuticals and Galena Biopharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eyegate Pharmaceuticals $767,481.00 22.86 -$13.31 million ($1.30) -0.78
Galena Biopharma N/A N/A -$23.48 million ($1.76) -0.21

Eyegate Pharmaceuticals has higher revenue and earnings than Galena Biopharma. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Galena Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eyegate Pharmaceuticals and Galena Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyegate Pharmaceuticals 0 0 4 0 3.00
Galena Biopharma 0 2 0 0 2.00

Eyegate Pharmaceuticals currently has a consensus price target of $7.33, indicating a potential upside of 618.95%. Galena Biopharma has a consensus price target of $2.78, indicating a potential upside of 651.55%. Given Galena Biopharma’s higher possible upside, analysts clearly believe Galena Biopharma is more favorable than Eyegate Pharmaceuticals.


Eyegate Pharmaceuticals beats Galena Biopharma on 7 of the 12 factors compared between the two stocks.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Galena Biopharma Company Profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.